Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
49 hedge funds and large institutions have $250M invested in Adaptimmune Therapeutics in 2015 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 19 increasing their positions, 2 reducing their positions, and 13 closing their positions.
850% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 2
62% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 13
38% more capital invested
Capital invested by funds: $181M → $250M (+$68.6M)
20% more funds holding
Funds holding: 41 → 49 (+8)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$28.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.4M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
+$6.53M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$5.68M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$16.9M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$12M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$7.84M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.42M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$1.33M |
ADAP Hedge Fund Activity: Q4 2015 in Review
49 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q4 2015, worth a combined $250M — up 38% from $181M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ADAP positions and 13 closed out — a net gain of 8 holders — while 19 added to existing stakes and 2 trimmed.
The largest buyer was Capital World Investors, adding an estimated $28.3M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $16.9M sold.
- 49 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q4 2015, up from 41 in Q3 2015.
- Funds reported $250M of Adaptimmune Therapeutics stock for Q4 2015, up 38% quarter-over-quarter.
- 21 funds opened new Adaptimmune Therapeutics positions in Q4 2015 and 13 closed out, a net change of +8 holders.
- The largest Adaptimmune Therapeutics buyer in Q4 2015 was Capital World Investors, an estimated $28.3M added.
- The largest Adaptimmune Therapeutics seller in Q4 2015 was Novo Holdings A/S, an estimated $16.9M sold.
Based on aggregated 13F filings for Q4 2015.